PainReform Ltd. (PRFX): Price and Financial Metrics


PainReform Ltd. (PRFX): $0.69

0.05 (+8.08%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

PRFX Stock Price Chart Interactive Chart >

Price chart for PRFX

PRFX Price/Volume Stats

Current price $0.69 52-week high $1.49
Prev. close $0.64 52-week low $0.34
Day low $0.66 Volume 37,300
Day high $0.70 Avg. volume 292,775
50-day MA $0.57 Dividend yield N/A
200-day MA $0.64 Market Cap 7.34M

PainReform Ltd. (PRFX) Company Bio


PainReform Ltd. operates as a pharmaceutical company. It develops and markets pharmaceuticals. The firm focuses on developing reformulation of pain therapeutics, PainReform applies its propriety formulation technologies to prolong and enhance efficacy, reduce adverse effects shortening recovery time and reduce the need of augmentation with drugs such as opioids and NSAIDS. The company was founded by Lihu Avitov and Dan Teleman in 2007 and is headquartered in Herzliya, Israel.


PRFX Latest News Stream


Event/Time News Detail
Loading, please wait...

PRFX Latest Social Stream


Loading social stream, please wait...

View Full PRFX Social Stream

Latest PRFX News From Around the Web

Below are the latest news stories about PAINREFORM LTD that investors may wish to consider to help them evaluate PRFX as an investment opportunity.

PainReform Completes First Part of Phase 3 Clinical Trial in Patients Undergoing Bunionectomy Surgery

First 15 patients administered PRF-110 intra-operativelyTEL AVIV, Israel, March 28, 2023 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced completion of treatment for the first part, of its two-part Phase 3 clinical trial of PRF-110, in which 15 patients were enrolled and administered PRF-110 intra-operatively to review surgeon’s handling o

Yahoo | March 28, 2023

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday

We're starting off the day with a look at the biggest pre-market stock movers traders need to know about on Tuesday morning!

William White on InvestorPlace | March 21, 2023

PainReform Provides Year-End Business Update; Commences Phase 3 Clinical Trial of PRF-110 in Bunionectomy

TEL AVIV, Israel, March 16, 2023 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today provided a business update for the year ended December 31, 2022. Ilan Hadar, Chief Executive Officer, stated, “We are pleased to report a number of important milestones this past year which have helped advance the clinical development of PRF-110, our lead drug candidat

Yahoo | March 16, 2023

PainReform Announces Commencement of Phase 3 Clinical Trial to Evaluate PRF-110 in Patients Undergoing Bunionectomy Surgery

Initial pharmacokinetic data on first 15 patients expected in May 2023TEL AVIV, Israel, March 14, 2023 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced that it has commenced a Phase 3 clinical trial of PRF-110, the Company’s lead drug candidate, targeting the post-operative extended pain relief market. The Phase 3 trial is a randomized, do

Yahoo | March 14, 2023

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

We're starting off Friday with an overview of the biggest pre-market stock movers traders will want to keep an eye on today!

William White on InvestorPlace | February 10, 2023

Read More 'PRFX' Stories Here

PRFX Price Returns

1-mo 24.08%
3-mo 67.19%
6-mo 6.15%
1-year -41.77%
3-year N/A
5-year N/A
YTD 67.19%
2022 -68.97%
2021 -70.25%
2020 N/A
2019 N/A
2018 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.985 seconds.